Document is current
Any future updates will be listed below
-
Authors
Zhang, Zhen https://orcid.org/0009-0006-4094-9271
Langenbach, Marlene
Sagar, Sagar https://orcid.org/0000-0002-8657-4704
Fetsch, Viktor https://orcid.org/0009-0006-2091-9999
Stritzker, Jonas
Severa, Elizabeth
Meng, Ke
Winkler, Frances
Rana, Nisha
Zoldan, Katharina
Godbole, Ira
Solis, Sabrina
Weber, Jeffrey S.
Rafei-Shamsabadi, David
Lehr, Saskia https://orcid.org/0000-0001-6551-2136
Diehl, Rebecca
Venhoff, Ana Cecilia
Voll, Reinhard E. https://orcid.org/0000-0002-5542-9133
Buettner, Nico
Neumann-Haefelin, Christoph https://orcid.org/0000-0001-7351-1387
Boettler, Tobias https://orcid.org/0000-0002-1195-055X
Hofmann, Maike https://orcid.org/0000-0001-8410-8833
Boerries, Melanie https://orcid.org/0000-0002-3670-0602
Meiss, Frank https://orcid.org/0000-0002-4044-9094
Zeiser, Robert https://orcid.org/0000-0001-6565-3393
Thimme, Robert https://orcid.org/0000-0003-1417-4135
Herati, Ramin S. https://orcid.org/0000-0003-2613-4050
Bengsch, Bertram https://orcid.org/0000-0003-2552-740X
- License Information
-
More Information
Article History
Received: 22 March 2023
Accepted: 28 October 2024
First Online: 19 December 2024
Competing interests
: F.M. served as consultant and/or has received honoraria or travel support from Novartis, Roche, BMS, MSD, Pierre Fabre and Sunpharma. D.R.S. served as consultant and/or has received honoraria from Roche and BMS and travel support from Sunpharma and Sanofi. R.Z. has received honoraria from Novartis, INcyte, MNK and Sanofi. R.V. has received honoraria or travel support from Abbvie, AstraZeneca, Galapagos, Janssen-Cilag, Novartis, Pfizer and Roche, and research grant support from Novartis and Pfizer. J.W. consulted for and received <US$10,000 per annum from Merck, Genentech, AstraZeneca, GSK, Novartis, Nektar, Celldex, Incyte, Biond, Moderna, ImCheck, Sellas, Evaxion, Pfizer, Regeneron and EMD Serono and received US$10,000–25,000 from BMS for membership on advisory boards. J.W. also held equity in Biond, Evaxion, OncoC4 and Instil Bio, was on the scientific advisory boards for CytomX, Incyte, ImCheck, Biond, Sellas, Instil Bio, OncoC4 and NexImmune, and was remunerated with between US$10,000 and US$50,000. In addition, J.W. is named on a patent filed by Moffitt Cancer Center on an ipilimumab biomarker and on tumor-infiltrating lymphocyte preparation, and on a PD-1 patent filed by Biodesix. J.W. received <US$6,000 in royalties. The remaining authors declare no competing interests.
